PURPOSE: To evaluate the clinical and immunologic outcomes of DC (dendritic cell) vaccine with interleukin (IL)-2 and IFN-alpha 2a in metastatic renal cell carcinoma patients. EXPERIMENTAL DESIGN: Eighteen consented and eligible patients were treated. Peripheral blood monocytes were cultured ex vivo into mature DCs and loaded with autologous tumor lysate. Treatment consisted of five cycles of intranodal vaccination of DCs (1 x 10(7) cells/1 mL Lactated Ringer's solution), 5-day continuous i.v. infusion of IL-2 (18MiU/m2), and three s.c. injections of IFN-alpha 2a (6MiU) every other day. Response Evaluation Criteria in Solid Tumors criteria were used for disease assessment. Correlative immunologic end points included peripheral blood lymphocyte cell phenotype and function as well as peripheral blood anti-renal cell carcinoma antibody and cytokine levels. RESULTS: All patients received between two and five treatment cycles. Toxicities consisted of known and expected cytokine side effects. Overall objective clinical response rate was 50% with three complete responses. Median time to progression for all patients was 8 months, and median survival has not been reached (median follow up of 37+ months). Treatment-related changes in correlative immunologic end points were noted and the level of circulating CD4(+) T regulatory cells had a strong association with outcome. Pre-IP-10 serum levels approached significance for predicting outcome. CONCLUSIONS: The clinical and immunologic responses observed in this trial suggest an interaction between DC vaccination and cytokine therapy. Our data support the hypothesis that modulation of inflammatory, regulatory, and angiogenic pathways are necessary to optimize therapeutic benefit in renal cell carcinoma patients. Further exploration of this approach is warranted.
PURPOSE: To evaluate the clinical and immunologic outcomes of DC (dendritic cell) vaccine with interleukin (IL)-2 and IFN-alpha 2a in metastatic renal cell carcinomapatients. EXPERIMENTAL DESIGN: Eighteen consented and eligible patients were treated. Peripheral blood monocytes were cultured ex vivo into mature DCs and loaded with autologous tumor lysate. Treatment consisted of five cycles of intranodal vaccination of DCs (1 x 10(7) cells/1 mL Lactated Ringer's solution), 5-day continuous i.v. infusion of IL-2 (18MiU/m2), and three s.c. injections of IFN-alpha 2a (6MiU) every other day. Response Evaluation Criteria in Solid Tumors criteria were used for disease assessment. Correlative immunologic end points included peripheral blood lymphocyte cell phenotype and function as well as peripheral blood anti-renal cell carcinoma antibody and cytokine levels. RESULTS: All patients received between two and five treatment cycles. Toxicities consisted of known and expected cytokine side effects. Overall objective clinical response rate was 50% with three complete responses. Median time to progression for all patients was 8 months, and median survival has not been reached (median follow up of 37+ months). Treatment-related changes in correlative immunologic end points were noted and the level of circulating CD4(+) T regulatory cells had a strong association with outcome. Pre-IP-10 serum levels approached significance for predicting outcome. CONCLUSIONS: The clinical and immunologic responses observed in this trial suggest an interaction between DC vaccination and cytokine therapy. Our data support the hypothesis that modulation of inflammatory, regulatory, and angiogenic pathways are necessary to optimize therapeutic benefit in renal cell carcinomapatients. Further exploration of this approach is warranted.
Authors: T Schwaab; J A Heaney; A R Schned; R D Harris; B F Cole; R J Noelle; D M Phillips; L Stempkowski; M S Ernstoff Journal: J Urol Date: 2000-04 Impact factor: 7.450
Authors: M S Ernstoff; S Nair; R R Bahnson; L M Miketic; B Banner; W Gooding; R Day; T Whiteside; T Hakala; J M Kirkwood Journal: J Clin Oncol Date: 1990-10 Impact factor: 44.544
Authors: Yanyan Lou; Gang Wang; Gregory Lizée; Grace J Kim; Steven E Finkelstein; Chiguang Feng; Nicholas P Restifo; Patrick Hwu Journal: Cancer Res Date: 2004-09-15 Impact factor: 12.701
Authors: P S Goedegebuure; L M Douville; H Li; G C Richmond; D D Schoof; M Scavone; T J Eberlein Journal: J Clin Oncol Date: 1995-08 Impact factor: 44.544
Authors: Anurag K Singh; Timothy B Winslow; Mohammad Habiby Kermany; Vincent Goritz; Lilia Heit; Austin Miller; Nicholas C Hoffend; Leighton C Stein; Lalith K Kumaraswamy; Graham W Warren; Wiam Bshara; Kunle Odunsi; Junko Matsuzaki; Scott I Abrams; Thomas Schwaab; Jason B Muhitch Journal: Clin Cancer Res Date: 2017-06-19 Impact factor: 12.531
Authors: Camilo E Fadul; Jan L Fisher; Thomas H Hampton; Enrico C Lallana; Zhongze Li; Jiang Gui; Zbigniew M Szczepiorkowski; Tor D Tosteson; C Harker Rhodes; Heather A Wishart; Lionel D Lewis; Marc S Ernstoff Journal: J Immunother Date: 2011-05 Impact factor: 4.456
Authors: Heike Pohla; Alexander Buchner; Birgit Stadlbauer; Bernhard Frankenberger; Stefan Stevanovic; Steffen Walter; Ronald Frank; Tim Schwachula; Sven Olek; Joachim Kopp; Gerald Willimsky; Christian G Stief; Alfons Hofstetter; Antonio Pezzutto; Thomas Blankenstein; Ralph Oberneder; Dolores J Schendel Journal: Mol Med Date: 2013-02-08 Impact factor: 6.354
Authors: Alexandre Harari; Michele Graciotti; Michal Bassani-Sternberg; Lana E Kandalaft Journal: Nat Rev Drug Discov Date: 2020-08-06 Impact factor: 84.694